Tolebrutinib slowed disability in secondary progressive MS
Key Takeaway
Tolebrutinib lowered the risk of worsening disability in people with secondary progressive MS who were not having relapses.
What They Found
About 23% of people taking tolebrutinib had lasting disability worsening, compared with about 31% taking a placebo (a pill with no active drug). Worsening had to last at least six months to count. Participants were followed for about 133 weeks. Serious health problems occurred in 15% taking tolebrutinib and about 10% taking the placebo. A liver test showed large increases more often with tolebrutinib than with the placebo.
Who Should Care and Why
The study included people with secondary progressive MS who were not having relapses. Researchers compared tolebrutinib with a placebo (a pill with no active drug). The study focused on disability worsening, not flare-ups. Fewer people taking tolebrutinib had disability worsening that lasted at least six months. Serious health problems and large increases on a liver test were more common in the tolebrutinib group.
Important Considerations
You should know this was a trial of 1,131 people, randomly assigned to tolebrutinib or a placebo (a pill with no active drug). Neither participants nor researchers knew which treatment each person received during the trial. The abstract does not say whether the serious health problems were caused by tolebrutinib.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The New England journal of medicine often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.